Elgubbi Amna S, El-Helw Eman A E, Alzahrani Abdullah Y A, Ramadan Sayed K
Chemistry Department, Faculty of Science, Misurata University 2478 Misurata Libya.
Chemistry Department, Faculty of Science, Ain Shams University Cairo 11566 Egypt
RSC Adv. 2024 Feb 15;14(9):5926-5940. doi: 10.1039/d3ra07048d. eCollection 2024 Feb 14.
Thiophene-2-carbohydrazide was used in this study to produce some thiophene-containing oxadiazole, triazole, and thiazolidinone derivatives through reactions with various carbon-centered electrophiles. Besides, the hydrazone obtained was allowed to react with mercaptoacetic acid and acetic anhydride to construct thiazolidinone and oxadiazole derivatives. The results of computational chemical study and outcomes of the experiments were in good agreement. The antiproliferative activity of the produced compounds was examined against two human cell lines namely, breast adenocarcinoma (MCF7) and colon cancer (HCT116) cell lines using doxorubicin as a reference anticancer agent. The produced hydrazones and spiro-indolin-oxadiazole derivatives were the most potent against the two cancer cell lines. The molecular docking was conducted to demonstrate the binding energies of produced substances toward human carbonic anhydrase IX (CA IX) protein. The binding energies of these ligands were near to that of the co-crystallized ligand (9FK). Compound 11b exhibits a binding energy of -5.5817 kcal mol, indicating tight binding to some key nucleobases and amino acids of CA IX protein, while compound 11a displays a higher binding energy compared to the reference ligand (9FK). This suggests that compounds 11b and 11a display a notably strong binding affinity towards the human carbonic anhydrase IX (CA IX) protein. ADME profiles of the potent compounds including physicochemical characteristics, lipophilicity, and drug-likeness were predicted.
在本研究中,噻吩 - 2 - 碳酰肼用于通过与各种碳中心亲电试剂反应制备一些含噻吩的恶二唑、三唑和噻唑烷酮衍生物。此外,所得腙与巯基乙酸和乙酸酐反应以构建噻唑烷酮和恶二唑衍生物。计算化学研究结果与实验结果吻合良好。以阿霉素作为参考抗癌剂,检测了所制备化合物对两种人类细胞系,即乳腺腺癌(MCF7)和结肠癌细胞系(HCT116)的抗增殖活性。所制备的腙和螺吲哚 - 恶二唑衍生物对这两种癌细胞系的活性最强。进行了分子对接以证明所制备物质对人碳酸酐酶IX(CA IX)蛋白的结合能。这些配体的结合能与共结晶配体(9FK)相近。化合物11b的结合能为 - 5.5817 kcal/mol,表明其与CA IX蛋白的一些关键核碱基和氨基酸紧密结合,而化合物11a与参考配体(9FK)相比具有更高的结合能。这表明化合物11b和11a对人碳酸酐酶IX(CA IX)蛋白表现出显著强的结合亲和力。预测了活性化合物的ADME概况,包括物理化学特性、亲脂性和药物相似性。